Top Stocks To Own Right Now


Potash producers Mosaic (MOS) and Potash Corp. (POT) have been hammered this year as changes to the market leave their shares wracked with uncertainty.

Reuters

That might be about to change, says JPMorgan analyst Jeffrey Zekauskas and team, who believe the end of the uncertainty is nigh. They write:

The endgame in potash industry dynamics appears now to have begun. Belarus wants a return to a price over volume dynamic for the potash industry, and the change of ownership of Uralkali is the crucial step for obtaining it. Suleiman Kerimov and his partners own a controlling interest in Uralkali and are now selling their controlling interests…The motivation of the sale of the Kerimov interest has been the dissatisfaction of the Russian government with the disruptions in its relations with Belarus caused by the volume-over-price strategy set in motion by the Kerimov-led Uralkali on July 31, 2013…

Top Stocks To Own Right Now: Controladora Vuela Compania de Aviacion SAB de CV (VLRS)


Controladora Vuela Compania de Aviacion SAB de CV (Volaris Aviation Holding Company) is a Mexico-based company principally engaged in the airline passenger transportation industry. The Company is a law-cost carrier airline. Controladora Vuela Compania de Aviacion SAB de CV offers direct, point-to-point flights. The Company serves through secondary, lower cost airports and provides a single class of service. The Company utilizes such aircraft as the Airbus A319 and A320 families, among others. The Company has such subsidiaries as Comercializadora Volaris SA de CV, Servicios Corporativos Volaris SA de CV, Concesionaria Vuela Compania de Aviacion SAPI de CV, Deutsche Bank Mexico SA Trust 1484, among others. Advisors’ Opinion:

  • [By John Udovich]

    When most American investors think of discount airline stocks, they probably think of relatively large capped Southwest Airlines Co (NYSE: LUV) or sort of small cap JetBlue Airways Corporation (NASDAQ: JBLU) rather than small cap Controladora Vuela Co Avcn SA CV (NYSE: VLRS) which owns Volaris – a discount airline serving the Mexican market. However, any investor who has read Benjamin Graham’s Intelligent Investor might want to remember his sage advice about avoiding airline stocks – mainly because airlines were such a new and unproven sector that had yet to make money. But could Controladora Vuela Co Avcn SA CV actually be an airline stock worth owning?

Top Stocks To Own Right Now: Dolby Laboratories Inc (DLB)


Dolby Laboratories, Inc., incorporated in 1967, develops and delivers products and technologies that are used in the entertainment industry. Its audio technologies are used throughout the global entertainment industry. It is developing and marketing video technologies to improve the quality of video presentation. Its offerings include video products aimed at the cinema market, such as its digital cinema server, its Dolby three-dimensional (3D) Digital Cinema products, and its Dolby PRM-4200 Professional Reference Monitor. It offers products and services to content creators, such as studios, broadcasters, and downloadable content service providers to encode content using Dolby’s technologies. As of September 24, 2010, the Company sold its products and provide services in over 85 countries. In addition, it has licensed its technologies to CE manufacturers and to software vendors in 40 countries, which in turn distribute their products incorporating its technologies through out the world.


The Company designs and manufactures video and audio products for the film production, cinema, and television broadcast industries. Distributed in over 60 countries, these products are used in content creation, distribution and playback to improve image and sound quality, provide surround sound, and increase the efficiency of sound storage and distribution. Its product sales are derived from sales of its digital 3D products, which provide 3D capabilities, as well as sales of digital cinema servers that load, store, decrypt, and decode encrypted digital film files for presentation on digital projectors in theaters. Revenue is also derived from sales of its traditional cinema processors, which movie theaters use to process film soundtracks, and from sales of broadcast products used to encode and distribute content to viewers. It also offers related digital cinema processors and media adapters to decode digital cinema soundtracks, and digital cinema accessories that allow exhibitors to integrate its digital ! cinema servers with their existing automation systems.


The Company offers a variety of services to support film production, television broadcast and music production. The Company enters into service agreements with motion picture studios or filmmakers to provide them with production services related to the preparation of a Dolby soundtrack, such as equipment calibration, mixing room alignment and equalization. Dolby provides other services, such as print quality control, professional film mastering services to prepare movies for digital release, and theatre system calibration for important screenings, such as premieres, film festivals, and press screenings. Its engineers also provide training, system design consultation and onsite technical expertise to cinema operators throughout the world to help them configure their screening rooms and equipment to ensure that movies are replayed with consistent high quality.


The Company’s technologies include dolby digital, dolby digital plus, dolby digital surround EX, dolby digital EX, advanced audio coding (AAC), HE AAC, dolby pulse, dolby trueHD, dolby E, dolby digital live, dolby pro logic II, dolby pro logic II(x), dolby pro logic IIz, dolby virtual speaker, dolby headphone, dolby mobile, dolby axon, PC entertainment experience (PCEE), dolby digital stereo creator, dolby digital 5.1 creator, dolby volume, dolby contrast, dolby vision and analog signal processing technologies. Its products include traditional cinema processors, digital cinema products, digital 3D products, digital media adapters, broadcast products and professional reference monitor.


Traditional cinema processors are used to read, decode and play back a film’s soundtrack and calibrate the sound system in a movie theater. Digital cinema products are used for digital cinema encoding, distribution and playback. Our digital cinema server is used to load, store, decrypt, decode and re-encrypt dig ital film files for presentation on a digital cinema project! or. We al! so provide products that encrypt, encode and package digital films, and digital cinema processors to decode digital cinema soundtracks. Digital 3D products deliver a 3D image with an existing digital cinema server and white screen, providing exhibitors a flexible 3D solution. Its Dolby 3D glasses feature high-quality multicoated lenses with a special curvature that delivers 3D images.


Digital media adapters are used to adapt existing analog cinema audio systems to the latest digital audio technologies. Broadcast products are used to encode, transmit and decode multiple channels of high-quality audio for Digital Television (DTV) and high-definition television (HDTV) program production and broadcast distribution and to measure the subjective loudness of audio content within broadcast programming. Professional reference monitor is a video monitor used during the production and post-production of cinematic and video content in situations, where grade one reference performance is required.


The Company competes with Audyssey Laboratories, DTS, Fraunhofer Institute for Integrated Circuits, Microsoft, Philips, RealNetworks, Sonic Solutions, Sony, SRS Labs, Thomson, Barco, Doremi, GDC, IMAX, MasterImage 3D, NEC, Panavision, QSC Audio Products, Qube Cinema, REAL D, Technicolor, Texas Instruments, USL, XpanD and DTS.

Advisors’ Opinion:

  • [By Sue Chang]

    Dolby Laboratories (DLB) : “The Hobbit: The Desolation of Smaug” is presented in Dolby Surround 7.1. The stock is up 28% so far in 2013.

  • [By Tim Melvin]

    Price’s new buys in the quarter were Oenok (OKE), Dolby Labs (DLB) and T-Mobile (TMUS). I don’t find any of those particularly exciting at current levels, but I’m willing to acknowledge that Michael Price is a lot smarter than I am and probably sees value I am missing in these stocks. What I find much more interesting was that Price was doing a lot more selling than buying in the third quarter.

  • [By Steve Symington]

    Enter Dolby 3D
    That’s why I’m so intrigued by Monday’s news that Dolby (NYSE: DLB  ) and Philips (NYSE: PHG  ) have collaborated in a joint project to create a new content delivery specification for the Dolby 3D format, which will be part of a “suite of technologies” to more easily allow content creators the ability to make, deliver, and play back glasses-free 3-D content.

Top Stocks To Own Right Now: Vertex Pharmaceuticals Incorporated(VRTX)


Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Advisors’ Opinion:

  • [By Garrett Cook]

    Vertex Pharmaceuticals (NASDAQ: VRTX) shares shot up 41.12 percent to $94.00 after the company reported that its two phase 3 studies of Lumacaftor in combination with ivacaftor met the primary endpoint.

  • [By Garrett Cook]

    Vertex Pharmaceuticals (NASDAQ: VRTX) shares shot up 42.73 percent to $95.07 after the company reported that its two phase 3 studies of Lumacaftor in combination with ivacaftor met the primary endpoint.

Top Stocks To Own Right Now: S&P Smallcap 600(PH)


Parker Hannifin Corporation manufactures fluid power systems, electromechanical controls, and related components worldwide. Its Industrial segment offers pneumatic and electromechanical components, and systems; filters, systems, and instruments to monitor and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors that control, transmit, and contain fluid; hydraulic components and systems for builders and users of industrial and mobile machinery and equipment; critical flow components for process instrumentation, healthcare, and ultra-high-purity applications; and static and dynamic sealing devices. This segment sells its products to original equipment manufacturers (OEMs) and their replacement markets in the manufacturing, transportation, and processing industries. The company?s Aerospace segment provides flight control systems and components, including hydraulic, electrohydraulic, electric backup hydraulic, electrohydrostatic, and electro -mechanical components for precise control of aircraft rudders, elevators, ailerons, and other aerodynamic control surfaces. It also provides electronics thermal management heat rejection systems, and single-phase and two-phase heat collection systems for radar, ISAR, and power electronics. This segment markets its products primarily to OEMs in the commercial, military, and general aviation markets, as well as to end users. Its Climate and Industrial Controls segment offers systems and components primarily for use in the mobile and stationary refrigeration, and air conditioning industry; and in fluid control applications in various industries, such as processing, fuel dispensing, beverage dispensing, and mobile emissions. This segment serves OEMs and their replacement markets. Parker-Hannifin Corporation markets its products through direct-sales employees, independent distributors, wholesalers, and sales representatives. The company was founded in 1918 and is headquartered i n Cleveland, Ohio.


Advisors’ Opinion:

  • [By Tom Rojas var popups = dojo.query(“.socialByline .popC”); popups.forEach(func]

    Parker Hannifin Corp.(PH) said its fiscal fourth-quarter earnings rose 11% on higher results in its diversified industrial segment as the company continued its restructure efforts.

  • [By Marc Bastow]

    Motion and control technology manufacturer Parker-Hannifan (PH) raised its quarterly dividend 7% to 48 cents per share, payable on Mar. 7 to shareholders of record as of Feb. 10.
    PH Dividend Yield: 1.69%

  • [By Lauren Pollock]

    Parker Hannifin Corp.’s(PH) fiscal second-quarter earnings rose 40% as the maker of motion and control equipment’s orders continued to grow and gains from a joint-venture agreement with General Electric Co.(GE) (GE) offset a costly write-down. Adjusted earnings were ahead of expectations, yet the company lowered its per-share earnings estimate for the year. Shares dropped 3.8% to $122 premarket.

  • [By Ben Levisohn]

    But don’t just buy any company, DeBlase says. Instead, focus on those that have EPS momentum, which has generated outperformance in 10 of the past 11 years, DeBlase says. As a result, investors should prefer Terex (TEX), her top pick, and Agco (AGCO), which she rates Outperform. John Deere (DE) and Parker Hannifin (PH) get tarred with Underweight ratings.

Top Stocks To Own Right Now: Spdr S&P Oil & Gas Exploration & Production Etf (XOP)


SPDR S&P Oil & Gas Exploration & Production Exchange Traded Fund (The Fund) seeks to replicate as closely as possible, before expenses, the performance of an index derived from the oil and gas exploration and production segment of a United States total market composite index. The Fund uses a passive management strategy designed to track the total return performance of the S&P Oil & Gas Exploration & Production Select Industry Index (the Oil & Gas Exploration Index).

The Oil & Gas Exploration Index represents the oil and gas exploration and production sub-industry portion of the S&P Total Market Index (TMI). The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange (NYSE), American Stock Exchange (AMEX), National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.


Advisors’ Opinion:

  • [By Richard Moroney]

    To uncover top picks, we looked for solid track records and reasonable expense ratios. Notable ETFs include SPDR S&P Oil & Gas Exploration & Production (XOP), Guggenheim S&P 500 Technology (BATS:RYT), and SPDR S&P Retail ETF (XRT).

Top Stocks To Own Right Now: MDC Partners Inc (MDCA)

MDC Partners Inc. (MDC), incorporated in 1986, is a provider of marketing communications services to customers worldwide. MDC has operating units in the United States, Canada, Europe and the Caribbean. The Company’s subsidiaries provide a range of marketing communications and consulting services, including advertising, interactive and mobile marketing, direct marketing, database and customer relationship management, sales promotion, corporate communications, market research, corporate identity, design and branding, social media and marketing, ecommerce and other related services. MDC operates in two segments: Strategic Marketing Services and Performance Marketing Services. Effective March 28, 2012, MDC invested in Doner Partners LLC (Doner). Doner is an integrated creative agency. In addition, the Company acquired a 70% interest in TargetCast LLC (TargetCast). TargetCast is a media agency. The Company acquired a 51% interest in Dotbox LLC (Dotbox). Effective January 8, 2 014, MDC Partners Inc acquired an undisclosed minority interest in Luntz Global LLC. In February 2014, MDC Partners Inc acquired an undisclosed majority interest in Kingsdale Shareholder Services Inc.


During the year ended December 31, 2011, the Company, through a wholly owned subsidiary, acquired RJ Palmer LLC and a 75% interest in Trade X Partners LLC (Trade X). In 2011, it entered into a transaction through its subsidiary Kwittken PR LLC (Kwittken) acquired 100% of Epoch PR Limited. In 2011, the Company also acquired a 51% interest in AIC Publishing Services LP (AIC). In addition, the Company increased its ownership to 85.3% of Veritas, to 94.0% of 656712 Ontario Limited (Onbrand), to 66.3% of 6Degrees Integrated Communications and 85% of Boom Marketing Inc. during 2011. In 2011, the Company increased ownership in Communifx Partners LLC (Communifx) by 1.3%, and increased its ownership of Varick Media Management LLC (Varick) to 100%. Effective January 31, 2011 , the Company, through a wholly owned subsidiary, purchased ! 60% interest in Anomaly Partners, LLC (Anomaly). Effective November 30, 2010, the Company, through a wholly owned subsidiary, purchased 80% interest in each of Kenna Communications LP and Capital C Partners LP.


Strategic Marketing Services

The Strategic Marketing Services segment consists of firms that offer a suite of integrated marketing communication and consulting services, including advertising and media, interactive marketing, direct marketing, public relations, corporate communications, market research, corporate identity and branding, and sales promotion to national and global clients. The Strategic Marketing Services segment consists of the agencies, such as 72andSunny; Allison & Partners; Anomaly; Attention; Bruce Mau Design; Capital C Partners; Colle + McVoy; Concentric Partners; Crispin Porter + Bogusky; Crispin Porter + Bogusky Canada; Hello Design; henderson bas kohn; HL Group Partners; kirshenbaum bond senecal + partners; Kbs+p Canad a; Kwittken; Laird + Partners; The Media Kitchen; Mono Advertising; Redscout; Sloane & Company; Varick Media Management; Veritas Communications; Vitro and Yamamoto.


Performance Marketing Services

The Performance Marketing Services segment includes firms that provide consumer insights. The Performance Marketing Services segment consists of agencies, such as 6degrees Communications; Accent; AIC Publishing; Boom Marketing; Bryan Mills Iradesso; Communifx Partners; Computer Composition; Hudsun Media; Integrated Media Solutions; Kenna Communications; Northstar Research Partners; Onbrand; Relevent; RJ Palmer; Source Marketing; TargetCom; Team and Trade X.

The Company competes with Omnicom Group Inc., Interpublic Group of Companies, Inc., WPP Group plc, Publicis Group SA and Havas Advertising.


Advisors’ Opinion:

  • [By Corinne Gretler]

    Petrofac Ltd. plunged 15 percent, the most in almost five years. Korian fell 3.8 percent after agreeing to buy Medica SA (MDCA) for 1.1 billion euros ($1.5 billion). Aberdeen Asset Management Plc jumped 13 percent after Lloyds Banking Group Plc agreed to sell its Scottish Widows Investment Partnership unit to the money manager. Sonova Holding AG advanced 6.9 percent as the world’s largest hearing-aid maker raised its full-year forecast after first-half revenue beat analyst estimates.

Top Stocks To Own Right Now: Genomic Health Inc (GHDX)


Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a R ecurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.


Oncotype DX Platform

The Company’s Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient’s tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient’! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.


Oncotype DX Breast Cancer Test

To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.


In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Coop erative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.


Oncotype DX Colon Cancer Test

The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and rec urrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.


The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.

Advisors’ Opinion:

  • [By John Udovich]

    Small cap genomics stocks Rosetta Genomics Ltd (NASDAQ: ROSG), Genomic Health, Inc (NASDAQ: GHDX) and CollabRx Inc (NASDAQ: CLRX) are at the forefront of genomics testing or research. I should mention that Wikipedia defines genomics as a discipline in genetics that applies recombinant DNA, DNA sequencing methods and bioinformatics to sequence, assemble and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). A 2013 Booz Allen Hamilton report on the sector noted that in 2011, the US genetic and genomic clinical testing market size was estimated to be $5.9 billion while the number of available tests has grown substantially from 1,680 just 4 years ago to 2,886 in 2012.

  • [By John Udovich]

    Small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped to a five year high on Wednesday thanks to good news that the government will be paying a heftier reimbursement for its main test than previously feared, meaning its worth taking a closer look at the stock along with small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should also mention that Myriad Genetics has been in our SmallCap Network Elite Opportunity (SCN EO) portfolio since early February and we are now up some 32.5% since then – thanks in part to the shorts being put in a short squeeze.

  • [By John Udovich]

    On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should mention that we have had Myriad Genetics in our SmallCap Network Elite Opportunity (SCN EO) portfolio since February 5th and we are already up 18.50% – a nice return in just two weeks time.

Top Stocks To Own Right Now: Nordson Corporation(NDSN)

Nordson Corporation manufactures equipment used for precision dispensing, testing and inspection, and surface preparation and curing. Its Adhesive Dispensing Systems segment manufactures equipment for applying adhesives, lotions, and liquids to disposable products; automated adhesive dispensing systems for the food and beverage, and packaged goods industries; hot melt and cold glue adhesive dispensing systems for the paper and paperboard converting industries; adhesive and sealant dispensing systems for bonding or sealing plastic, metal, and wood products; and laminating and coating systems to manufacture continuous-roll goods in the nonwovens, textile, paper, and flexible-packaging industries. The company?s Advanced Technology Systems segment comprises automated gas plasma treatment systems used to clean and condition surfaces for the semiconductor, medical, and printed circuit board industries; controlled manual and automated systems for applying materials in customer pr ocesses requiring precision and material conservation; ultraviolet equipment used in curing and drying operations for specialty coatings, semiconductor materials, and paints; and bond testing and automated optical and x-ray inspection systems used in the semiconductor and printed circuit board industries. Its Industrial Coating Systems segment provides automated and manual dispensing systems used for applying coatings, paint, finishes, sealants, and other materials. Nordson Corporation markets its products in the United States and internationally through a direct sales force, as well as through qualified distributors and sales representatives. It serves various markets, including the appliance, automotive, bookbinding, container, converting, electronics, food and beverage, furniture, life sciences and medical, metal finishing, non woven, packaging, and semiconductor industries. The company was founded in 1935 and is headquartered in Westlake, Ohio.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Nordson Corp.’s(NDSN) fiscal fourth-quarter earnings fell 12% on weaker demand, though the maker of dispensing equipment noted improvement in recent order trends.

  • [By Travis Hoium]

    What: Shares of industrial product manufacturer Nordson (NASDAQ: NDSN  ) dropped as much as 10% today after the company reported fiscal second-quarter earnings.